Related Experiment Videos

Atenolol and three nonselective beta-blockers in hypertension

Insights

Cardioselective atenolol showed potential advantages over noncardioselective beta-blockers in hypertension treatment. Atenolol lowered diastolic blood pressure and serum creatinine, with no significant impact on lung function or glucose tolerance.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertension management often involves beta-blockers.
  • Cardioselective beta-blockers offer targeted action, potentially reducing side effects compared to noncardioselective agents.

Purpose of the Study:

  • To compare the efficacy and safety of cardioselective atenolol versus noncardioselective beta-blockade in treating hypertension.
  • To evaluate effects on blood pressure, heart rate, and various biochemical markers.

Main Methods:

  • A crossover trial involving 27 hypertensive patients previously controlled on nonselective beta-blockers.
  • Patients were randomized to receive either atenolol or their previous nonselective beta-blocker for 8 weeks.
  • Evaluations included blood pressure, pulse rate, spirometry, glucose tolerance, lipid profiles, and stress tests.

Main Results:

  • Atenolol, at equivalent systolic blood pressure lowering doses, resulted in lower diastolic blood pressure at rest and during stress.
  • Serum creatinine levels were lower with atenolol compared to noncardioselective beta-blockers.
  • No significant differences were observed in lung function or glucose/insulin levels, even in diabetic patients.

Conclusions:

  • Cardioselective atenolol may offer benefits in hypertension management, including improved diastolic blood pressure control and reduced serum creatinine.
  • Atenolol demonstrated a favorable profile regarding metabolic and respiratory parameters in this patient cohort.

Related Concept Videos